All In Biotech

Drug Trial Radar · NCT06866977

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Mar 12, 2025

Primary completion

Oct 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Xiangya Hospital of Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guangzhou Virotech Pharmaceutical Co., Ltd.
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, single-arm, open label investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of advanced pancreatic cancer.

Conditions

  • Pancreatic Cancer

Interventions

  • Oncolytic virus VRT106Drug

    VRT106, IV

  • ChemotherapyDrug

    21 days/cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: About 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.